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Objectives: The surgical site infection (SSI) is the most often acquired hospital 
infection in Spain, about 19.4% of all nosocomial infections. The prevalence of this 
adverse event is 8.01%, generating high economic impact on hospital costs and 
undermining the quality of care. The risk of SSI has increased in recent years and 
infections have become more resistant to treatments. About 50% of SSIs are pre-
ventable, their costs are avoidable, and health technology can help avoiding them. 
The aim of this study is to analyze the economic impact that could represent the 
use of anti-bacterial sutures compared with conventional ones in Spanish hospi-
tals. MethOds: An interactive Excel model was developed using data obtained 
through a published literature review. The rate of reduction of SSI with antibacte-
rial suture is 30%. The incremental cost per patient with SSI is between € 9,657 and 
€ 10,112.63. Two scenarios were designed: 100% of surgeries with normal sutures and 
100% of surgeries with anti-bacterial sutures. A sensitivity analysis for the variables 
of greatest uncertainty was performed (cost per SSI). Results: The budget impact 
of the use of antibacterial sutures resulted in a 24% of cost savings related to the 
normal sutures. It represents savings of € 5.4M per year for an average Spanish 
hospital, and € 1,264M per year for the whole Spanish Health System. The results of 
the sensitivity analysis shows that even by changing the effectiveness of the suture 
and using the most unfavourable data found in the literature for the cost of an SSI, 
the use of the antibacterial suture still produces savings of 24% compared with the 
use of normal suture. cOnclusiOns: This budget impact analysis provides new 
evidence that reinforces the use of antibacterial sutures, because it may reduce 
the risk of SSI, the negative effects of its consequences and associated costs and 
significantly improving the quality of care for surgical patients in Spain.
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Objectives: The 2013 WHO-guidelines recommend viral load (VL) monitoring plus 
CD4-count monitoring for patients on antiretroviral treatment (ART) in resource-
limited settings. We calculated the budget impact (BI) of VL monitoring strategies 
at the Infectious Diseases Institute (IDI), a large urban HIV program in Kampala, 
Uganda. MethOds: We calculated cost for the first 2 years of ART (drugs/tests/
staff) for three strategies: (1) Immunologic monitoring, standard of care (SOC): 
6-monthly CD4-count (2) New WHO-guidelines: SOC plus 6-monthly VL (3) A novel 
strategy: exclusive-VL (no CD4-counts after ART start), with VL at 3-months (to 
support adherence monitoring) and at 24 months. Patients with VL > 400copies/ml 
VL at 3-months will receive adherence counseling and repeat VL at 6-months. All 
costs are current actual costs at IDI and presented as 2012 USD ($): CD4-count= $9; 
VL= $65; first-line patients $206/year in year-1 and $272/year in year-2; second-line 
patients= $1381/year. For each strategy, rates of switch to second-line were estimated 
using IDI clinic data (1) SOC: 27%, 29%, 32% at 6, 12, 18 months (2) WHO-guidelines: 
7.3%, 10.8%, 13.8% at 6, 12, 18 months (3) Exclusive-VL: 21% at 3 months, 8.3% at 
6 months. Results: The cost per patient for the first 2 years of ART and BI of VL 
monitoring are (1) SOC: $572 (2) WHO- guidelines $897, BI $325 (3) Exclusive VL: 
$720, BI $148. Exclusive VL-monitoring results in a lower BI by supporting adher-
ence and averting ART failure. Increased cost with VL-monitoring is driven by more 
patients switching timely to second-line treatment with the cost of 2nd-line patients 
being 3.6 times higher for the new WHO-guidelines and 2.8 times higher for the 
exclusive-VL compared to SOC, rather than VL tests. cOnclusiOns: Implementing 
VL-monitoring strategies result in modest BI (26%-57%). Since switching timely to 
second-line benefits patients, similar programs should consider allocating resources 
to VL monitoring.
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Objectives: Invasive pneumococcal disease (IPD) is a major public health chal-
lenge. This study aims to perform a budget impact analysis (BIA) of 13-valent 
pneumococcal conjugated vaccine (PCV13) in adults immunocompromised (IC) or 
with comorbidities (CM), from a public payer perspective in Brazil. MethOds: BIA 
using a Markov model framework estimated the incremental costs of a vaccination 
program over a 10 year period comparing PCV13 versus PPSV23 or no vaccination 
in adults ≥ 18 years with CM or IC. Population size was calculated from Brazilian 
Institute of Geography and Statistics (IBGE) projections for 2014-2023 period and 
prevalence of risk groups were extracted from literature. Efficacy data for PCV13 
and PPSV23 were based on published data. Direct medical costs obtained from the 
literature included hospital days, medical fees, outpatient visits, diagnostic tests, 
and drugs in Brazilian Real (BRL). PCV13 and PPSV23 costs per dose were 52.40BRL 
and 23.00BRL, respectively. Results: Eligible population consisted of 15,241,353 
(CM) and 1,305,794 (IC) patients, for the 10-year period. After vaccination with PCV13, 
111, 869 (CM) and 42,786 (IC) IPD cases were avoided versus PPSV23 and 110,208 (CM) 
and 40,224 (IC) IPD cases versus no vaccination. Incremental costs per patient were 
52.02BRL (CM), and 51.92BRL (IC), for vaccination with PCV13 versus non vaccination, 
leading to a budget impact of 793,005,843BRL (CM) and 67,805,835 (IC) for the 10-year 
into single estimates (with confidence intervals for sensitivity analyses). The pur-
pose of this study is to investigate various methodologies for synthesizing data 
used as inputs into an economic model, based on a systematic review of a specific 
disease incidence. MethOds: A random-effects meta-analysis was conducted to 
estimate herpes zoster incidence from a systematic literature review of herpes 
zoster incidence in Europe. Since incidence could potentially be explained by some 
study-specific characteristics meta-regression was investigated. The variable of 
interest was predicted based on the year of data collection, country, age-group and 
study design. As incidence (expressed as annual probability) is typically bounded 
by 0 and 1, a logistic function was used to model the link between the predicted 
variable and its predictors. Results: Statistical tests suggested that data from 
some studies were outliers and were thus inconsistent with the model. A significant 
positive correlation was observed between age and herpes zoster incidence. The 
model allows for trends in incidence data to be explored based on country, year of 
data collection, study design and age. cOnclusiOns: This project investigated 
the use of meta-analysis and meta-regression for synthesizing data coming from 
various sources identified through a systematic review. Limitations were identified 
for both approaches. However, the meta-regression analysis can be used to estimate 
the current incidence of a particular disease, for a specific age group and country. 
It could help health economists in populating models and, subsequently, decision 
makers in their evaluation and assessments.
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Objectives: Development of highly active antiretroviral treatment (ART) had 
revolutionized the care of Human Immunodeficiency virus (HIV) -infected patients 
and led to marked reductions in HIV-associated morbidity and mortality in many 
developed countries. Hence this study aimed to analyze the predictors for mortal-
ity among patients living with HIV and who are on Antiretroviral Therapy (ART) in 
a south Indian hospital. MethOds: A retrospective cohort study was conducted 
on 350 patients infected with HIV were admitted to Asha Kirana Hospital, Mysore-
South India for a period of three years. Patients who died in the hospital during 
the study period (n-80) were compared with patients who had survived (n-270). 
Both groups were matched for age and sex. Predictors for death were analyzed by 
chi-square test using bivariate regression in software SPSS version 21. Results: 
Predictors for death in this study were increasing age > 60 years (RR), (95% CI) 2.204, 
(1.15-4.21), CD4 count < 200 cells 2.14 (1.26-3.13), patients without opportunistic 
infections- 1.80 (1.23- 2.63), WHO stage IV 1.83 (1.25-2.67) and being on stavudine 
based ART 2.01 (1.44-2.81). Patients with under-weight 1.33 (0.88-1.99) also found 
be risk for mortality, but it is not statistically significant. Factors associated with 
survival benefit were female sex 0.81 (0.55-1.19), patients without ART toxicity 0.78 
(0.51-1.20) and being on Tenofovir based regimen 0.8 (0.79-0.96). cOnclusiOns: 
Predictors for mortality among HIV patients on ART were found to be patients age 
> 60 years, CD4 count < 200 cells, WHO stage IV, absence of opportunistic infec-
tions and patients on Stavudine therapy. The absence of opportunistic infections 
being a risk factor may be due to undiagnosed opportunistic infections due to 
limited diagnostic facility as in this study setting. Patients on Tenofovir having 
survival benefit support the 2013 WHO recommendation for Tenofovir being the 
preferred regimen.
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meta-analySIS
Raman G.1, Avendano E.2, Berger S.2, Menon V.3, Bartlett J.4
1Tufts University School of Medicine; Tufts Medical Center, Boston, MA, USA, 2Tufts Medical 
Center, Boston, MA, USA, 3Cubist Pharmaceuticals, Lexington, MA, USA, 4Johns Hopkins 
University School of Medicine, Baltimore, MD, USA
Objectives: The rapid global spread of multi-resistant bacteria and loss of anti-
biotic effectiveness increases the risk of initially inappropriate antibiotic therapy. 
We examined the effects of use of appropriate or inappropriate antibiotic ther-
apy on outcomes in Gram-negative infections. MethOds: We searched Medline, 
Cochrane Central, and Embase databases through March 2014 for English-language 
studies that quantified effects of use of appropriate or inappropriate antibiotic 
therapy on all-cause mortality, length of stay, hospital costs, treatment failure, or 
bacterial clearance in hospitalized patients with complicated urinary tract infec-
tion, complicated intra-abdominal infection, bacteremia and pneumonia due to 
Gram-negative pathogens. We screened citations in duplicate and resolved dif-
ferences by consensus. We used random effect models meta-analysis when at 
least 3 studies reported the same outcome. Results: Forty-five studies with 1895 
patients were eligible. The definition of initial appropriate antibiotic therapy varied 
across studies. In meta-analyses of unadjusted data, initial appropriate antibiotic 
therapy was associated with lower risk of mortality (26 studies, 3713 patients, odds 
ratio (OR) 0.52, 95% confidence interval (CI) 0.41– 0.66) and treatment failure (3 
studies, 283 patients, OR 0.22, 95% CI 0.14– 0.35). In meta-analyses of adjusted data, 
initial appropriate therapy was associated with lower risk of mortality (5 studies, 
1211 patients, OR 0.50,95% CI 0.25–1.00), and conversely, initial inappropriate ther-
apy increased risk of mortality (16 studies, 2493 patients, OR 3.30, 95% CI 2.42–4.49) 
and decreased bacterial clearance. There were insufficient data to evaluate the 
impact on resource utilization and economic outcomes. cOnclusiOns: Initial 
inappropriate therapy is associated with an increased risk of hospital mortality. 
The paucity of new and effective antibiotics to cover resistant Gram-negative 
pathogens increases the likelihood of initial inappropriate therapy and poses a 
serious threat to patient safety. Critical gaps include lack of information on the 
health and economic burden of resistance.
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scenarios when compared to PCV13 alone [-328 (-1.6%) to 2,268 (9,2%) and from 
-10,145 (-8.9%) to 3,972 (4%) for IPD and NBPP respectively]. From a budget impact 
standpoint, none of the scenario was found in favor of PCV13. Under conservative 
vaccination coverage assumptions, the total incremental budget impact if PCV13 
replace PPV23 for the immunocompetent population ranged from € 39.8 million to 
€ 69.3 million. cOnclusiOns: With the epidemiological changes of pneumococcal 
diseases and the wider serotype coverage of PPV23, vaccination of at risks adults 
with PPV23 remains the optimal one strategy from a public health perspective. 
Moreover, in the current health budget constraint, PCV13 alone is found to be associ-
ated with a significant impact on budget, whereas the health benefits are limited.
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Objectives: This study aimed to evaluate the impact of pneumonia, meningitis 
and sepsis and the how they represent the costs for patients 50 years and older in 
the Brazilian Private Health System. MethOds: An administrative claims database 
containing over 18 million lives was used to identify episodes of pneumonia, men-
ingitis and sepsis, in all ages, between Oct/2010 and Dec/2013. The episodes were 
identified using ICD-10 codes of A40.3; B95.3; G00.1; J13; J15; J15.0; J15.3; J15.4; J15.8; 
J15.9; J18; J18.0; J18.9; J20.2 and P23.3 for pneumonia, A40; A40.0; A40.1; A40.8; A40.9; 
A41.8; A41.9; P36; P36.0 and P36.1 for sepsis, G00 and G00.9 for meningitis. Patients 
aged ≥ 50 years were identified and all-cause costs were extracted and grouped 
according to the 3 disease conditions. Results: A total of 70,850 patients were 
identified (pneumonia: 68,717; sepsis: 1,745; meningitis: 388, representing 96.99%, 
2.46% and 0.55% respectively). Different diseases disproportionately affected the 
populations. For pneumonia, 11.71% of episodes were in the ages 50+. Meningitis 
and sepsis represents 5.15% and 42.35%, respectively. The cost burden was also dif-
ferent by disease. Pneumonia had 56.95% of costs incurred by age 50+. For sepsis 
and meningitis, 75.8% and 15.53% of the costs were incurred by age 50+, respec-
tively. cOnclusiOns: Pneumonia, meningitis, and sepsis and its associated costs 
disproportionately affect the population in the Brazilian private health system. In 
particular, proportion of all pneumonia from patients age 50+ was only 11.71%, yet, 
the majority of expenditure (56.95%) for pneumonia patients is in the ages 50+. 
Pneumonia prevention strategies, including vaccinations, targeting adults age 50+, 
could potentially reduce health care costs associated with this condition.
PIn28
economIc ImPact of dengue ePISode: multIcenter Study acroSS four 
brazIlIan regIonS
Martelli C.M.T.1, Zara A.L.S.A.2, Oliveira C.S.3, Braga C.1, Pimenta F.G.J.4, Cortes F.J.M.1, Siqueira 
J.B.J.2, Bahia L.R.5, Mendes M.C.O.4, Rosa M.Q.M.5, Parente M.P.P.D.6, Siqueira N.T.F.1, Souza W.V.1
1Fundacao Oswaldo Cruz CPqAM Pernambuco, Recife, Brazil, 2Universidade Federal de Goias, 
Goiania, Brazil, 3Universidade do Estado do Para, Belem, Brazil, 4Secretaria Municipal Saude Belo 
Horizonte, Belo Horizonte, Brazil, 5Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 
6Universidade Estadual do Piaui, Teresina, Brazil
Objectives: To evaluate the economic burden of dengue from public payer and soci-
etal perspectives in Brazil. MethOds: Investigation was designed as a multicenter 
cost study. Suspected dengue cases were recruited during 2012/2013 in four endemic 
regions (city): Midwest (Goiania), Southeast (Belo Horizonte and Rio de Janeiro), 
Northeast (Teresina and Recife), North (Belem). Participants were suspected or labo-
ratory confirmed dengue cases, treated in ambulatory or hospital settings (private 
and public sectors). A household interview was scheduled 20-30 days after the onset 
of clinical symptoms. The time horizon was one-year considering dengue seasonality. 
We calculated the direct cost, public payer perspective and direct/indirect costs for 
societal perspective. Estimation of annual national dengue costs took into account 
cases reported by notification system (SINAN) having possible under-reporting from 
passive surveillance. Results: We screened 2,223 patients and 2,097 (94.3%) sympto-
matic dengue cases were included. The majority of patients were adults. 1,661 cases 
were treated in ambulatory and 436 cases in hospitals. In the ambulatory cohort, the 
average number of medical visits ranged from 1.2 to 4.2. A higher number of medical 
visits were recorded among inpatients (3.2 to 5.0). For the public payer perspective, 
estimated cost per case was USD 43 (95% CI: 39-47) ambulatory and USD 237 (95% 
CI: 202-248) hospital. Dengue illness in Brazil was estimated to cost USD 126 million 
(95% CI: 112-135), ambulatory and hospitalized cases considering the reported cases 
(SINAN). Outpatients cost account for 62% of the total costs. For the societal perspec-
tive, the estimated cost per ambulatory case was USD 163 (95% CI: 142-169) and USD 
465 (95% CI: 407-591) hospital. Dengue illness was estimated to cost USD 389 million 
(95% CI: 339-425), ambulatory and hospitalized cases. cOnclusiOns: Our results 
show evidence of substantial economic impact in Brazil. We have provided a timely 
economic evaluation of dengue.
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Objectives: Hepatitis A virus (HAV) infection is self-limiting with no chronic 
complications but in some cases might be very severe causing significant number 
of deaths. The results of a previously conducted cost-benefit analysis demon-
strated that the vaccination of all 1-year old children in the general population 
would be cost-effective to the health care system only in the years with an epi-
demiologic outbreak. The question remains will it be cost-effective in population 
period. For vaccination with PCV13 versus PPSV23, incremental costs per patient 
were 29.13BRL (CM) and 28.97BRL (IC) leading to a budget impact of 444,074,277BRL 
(CM) and 37,846,568BRL (IC) for the same period. cOnclusiOns: The addition of 
PCV13 to the immunization schedule in adults ≥ 18 years with comorbidities or 
immunocompromising condition would avoid more IPD cases, with an incremental 
cost varying from 37,846,568BRL to 793,005,843BRL over a 10 year period.
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trIcloSan coated antIbacterIal Suture: a budget ImPact analySIS 
from ItalIan health ServIce PerSPectIve
Velleca M.1, Socievole G.1, Muehlendyck C.2
1Johnson & Johnson Medical, Pomezia (RM), Italy, 2Johnson & Johnson Medical Gmbh, Norderstedt, 
Germany
Objectives: Triclosan coated antibacterial sutures (TCS) are designed to control 
the bacterial colonization of the suture line, a known risk factor for surgical site 
infection (SSI). A recently published meta-analysis came to the conclusion that TCS 
showed a significant advantage in reducing the rate of SSI by 30 per cent (relative 
risk 0·70,95 per cent C. I. 0·57 to 0·85; P < 0·001). Subgroup analyses revealed con-
sistent results in favour of TCS in adult patients, abdominal procedures, and clean 
or clean-contaminated surgical wounds. A budget impact analysis (BIA) has been 
developed to estimate the cost saving associated with use of new technology from 
the Italian Health Service perspective over a 1 year time horizon. MethOds: A lit-
erature review has been conducted to evaluate the potential impact of cost savings 
associated with SSI reduction in different procedures: Abdominal Hysterectomy; 
CABG; Colorectal Surgery; Hip Prothesis; Limb Amputation; Small Bowel Surgery. 
The means and 95% confidence interval (CI) for the BIA were estimated using boot-
strap methods (10.000 simulations) assuming lognormal distribution for costs and 
time data, and beta distribution for percentage data. Results: Potential cost sav-
ings per procedure with TCS would be 86€ for Abdominal Hysterectomy, 49€ for 
CABG, 141€ for Colorectal Surgery, 132€ for Hip Prothesis implantation, 415€ for 
Limb Amputation, 258€ for Small Bowel Surgery. Considering the annual procedures 
performed, the use of TCS, could be associated with cost saving of about 26.110.195 € 
(95%-CI: 10.574.295€ - 41.429.481€ ): 10% for Abdominal Hysterectomy; 1% for CABG; 
30% for Colorectal Surgery; 15% for Hip Prothesis; 34% for Limb Amputation and 8% 
for Small Bowel Surgery. cOnclusiOns: The additional costs for TCS appear to be a 
cost-saving through the reduction of costs associated with SSI allowing budget to be 
reallocated for other activities within the Health Service/Hospital. The results were 
consistent according to the developed probabilistic sensitivity analysis.
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Objectives: Analyse the budget impact in Region Hovedstaden in Denmark (Region 
H), if all Clostridium difficile (CDI) hospitalised patients received fidaxomicin instead 
of vancomycin during one year. MethOds: The Danish national patient database 
provided the number of hospitalised patients and length of stay (LOS) for CDI patients 
(ICD-10: A047). A phase III trial provided the risk of a first and second CDI recur-
rence [Cornelly 2012]. Cost per hospital stay calculated by LOS multiplied by cost 
per bed day (DKK 6,000) plus drug costs, vancomycin (DKK 300), fidaxomicin (DKK 
11,641). Results: In Region H 840 CDI patients were hospitalised in 2012. Assuming 
the same outcome as the trial, the total number of CDI hospitalisations would 
decrease from 1,104 with vancomycin ((23,2% risk of 1st recurrence (23.2% *840 = 195); 
35.5% risk of 2nd recurrence (35.5%*195 = 69)) to 930 with fidaxomicin ((9.0% risk of 1st 
recurrence (9.0%*840= 76); 19.7% risk of 2nd recurrence (19.7% *76= 15)). Fidaxomicin 
prevents 174 hospitalisations compared to vancomycin. Assuming CDI is the primary 
diagnosis, with an average LOS of 9.0 days, the health care cost will increase by 2% 
with fidaxomicin. Assuming CDI is the secondary diagnosis, with an average LOS of 
16.8 days, the health care cost will decrease by 6% with fidaxomicin. Assuming the 
average LOS for CDI patients is 13.3 days, the health care cost will decrease with 4%, 
and assuming LOS is 10 days, using fidaxomicin is cost neutral. cOnclusiOns: In 
Region H, if all hospitalised CDI patients received fidaxomicin the number of recur-
rences decreases by 66% and the total number of cases decreases by 16%, compared to 
vancomycin usage. From the health care payer perspective fidaxomicin reduces recur-
rences, frees up available bed days, and may be cost neutral or cost saving depending 
on the assumed LOS, compared to vancomycin.
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Objectives: In 2002 routine vaccination with a pneumococcal conjugate vaccine 
(PCV) was introduced in the French vaccination calendar for infants and toddlers. 
Since then, an ecological impact has been observed in the incidence of pneumococ-
cal diseases in adults: incidence of invasive pneumococcal disease (IPD) of sero-
types covered by PCV decreased, and serotypes not covered by PCV increased. This 
study aimed to quantify public health and budget impact of several pneumococ-
cal vaccination strategies for at-risk adults in France over 5 years. MethOds: The 
analysis was adapted from a population-based Markov model previously developed 
for Germany, consisting of five health states: no pneumococcal disease, IPD, non-
bacteraemic pneumococcal pneumonia (NBPP), post-meningitis sequelae and death. 
Epidemiology and costs were estimated from French sources whenever available. 
Uncertainty around vaccines effectiveness was handled using optimistic and/or 
pessimistic scenario analyses. At-risk adults received either PPV23 (for the immu-
nocompetent) or PCV13 (for the immunosuppressed). This strategy was compared 
to PCV13 vaccine alone. Results: Between 2014 and 2018, vaccination with PPV23 
and PCV13 led to a higher reduction in terms of IPD and NBPP cases avoided in most 
